Karl Pfleger
angel24 recorded companies
Healthspan Capital
vc16 recorded companies
Formic Ventures / Michael Antonov
vc13 recorded companies
Kizoo Tech Ventures
vc12 recorded companies
LongevityTech Fund
vc12 recorded companies
VitaDAO
angel12 recorded companies
LongGame
angel9 recorded companies
Bioverge
angel8 recorded companies
Methuselah Fund / Foundation
nonprofit8 recorded companies
Longevity Fund / age1
7 recorded companies
quadraScope / Fiona Miller
vc7 recorded companies
100+ Capital / Sonia Arrison
vc6 recorded companies
FightAging! / Reason
vc6 recorded companies
Lifespan Vision Ventures
vc6 recorded companies
Longevity Fund / age1 (as of Sep 2023)
vc6 recorded companies
Jim Mellon
angel6 recorded companies
R42 Group / Ronjon Nag
vc6 recorded companies
Starbloom Capital
vc6 recorded companies
Bold Capital
vc5 recorded companies
LongeVC
angel5 recorded companies
Shanda Venture Capital
vc5 recorded companies
Longevity Vision Fund
vc4 recorded companies
Metaplanet
angel4 recorded companies
Juvenescence
angel4 recorded companies
Thynk Capital / Jim Plante
vc4 recorded companies
Emerging Longevity Ventures
vc3 recorded companies
Prime Movers Lab
angel3 recorded companies
Ahren Capital
vc2 recorded companies
Apollo Health Ventures
vc2 recorded companies
Hevolution
nonprofit2 recorded companies
Presight Capital
vc2 recorded companies
Remiges Ventures
vc1 recorded companies
Dementia Discovery Fund
vc0 recorded companies
Longevity Venture Fund I
vc0 recorded companiesScottsdale, Arizona, USA
Early-stage regenerative medicine, cell therapies, organ transplantation, epigenetic reprogramming, AI drug discovery, peptides, and iPSC manufacturing
Khosla Ventures
vc0 recorded companies
Multi-sector venture capital with aging-biology investments in senescent-cell therapeutics, canine lifespan extension, epigenetic medicine, stem-cell manufacturing, and engineered organs
Healthspan Ventures
vc0 recorded companies
Pre-seed and seed investment in longevity biology, AI therapeutics, diagnostics, regenerative medicine, scientific tools, and human performance
Immortal Dragons
0 recorded companies
Radical life extension technologies including gene therapy, tissue engineering, organ replacement, regenerative medicine, neuroprotection, and healthspan
Maximon
0 recorded companiesZug, Switzerland
Longevity company building and early investment across science-based supplements, personalized diagnostics and treatment, preventive health, and healthy-aging services
Korify Capital
vc0 recorded companies
Longevity, mental health and regenerative medicine; Series A to C investing.
ARCH Venture Partners
vc0 recorded companies
Science-based venture investing with portfolio exposure to cellular rejuvenation, mitochondria and neurodegeneration.
Leaps by Bayer
corporate0 recorded companies
Strategic life-science investment including regenerative cell therapies, neurodegeneration and chronic inflammation.
Sofinnova Investments
vc0 recorded companies
Healthcare and life-science investing with a documented investment in BioAge Labs and its therapeutics targeting the biology of aging.
RA Capital Management
vc0 recorded companies
Multi-stage healthcare investing with a documented investment in BioAge Labs.
Jetstream Venture Fund
vc0 recorded companies
Venture investing with exposure to gene therapy for chronic and age-related diseases and animal health.
Kendall Capital Partners
vc0 recorded companies
Early-stage biotechnology and life sciences, including gene therapy for age-related disease.
VCapital
vc0 recorded companies
Venture investing with exposure to gene therapy for age-related disease and companion-animal health.
KdT Ventures
vc0 recorded companies
Venture investing with documented exposure to age-related disease gene therapy.
Digitalis Ventures
vc0 recorded companies
Venture investing with exposure to human and companion-animal health through age-related disease gene therapy.
Dolby Family Ventures
vc0 recorded companies
Early-stage precision neuroscience and life-science platforms, including mitochondrial quality control.
Versant Ventures
vc0 recorded companies
Biotechnology venture creation and investing, including regenerative cell therapies.
Founders Fund
vc0 recorded companies
Broad technology venture capital with a documented investment in epigenetic-reprogramming therapeutics through NewLimit.
Kleiner Perkins
vc0 recorded companies
Broad venture capital with a documented investment in aging-biology therapeutics through NewLimit.
Dimension
vc0 recorded companies
Science-and-compute investment firm with a documented investment in NewLimit's cellular-reprogramming platform.
Goldcrest Capital
vc0 recorded companies
Broad venture capital with a documented investment in Junevity's cell-reset and siRNA therapeutics platform.
Connecticut Innovations
vc0 recorded companies
State-backed venture investment with documented exposure to gene therapies for age-associated and chronic disease through Rejuvenate Bio.
Brandon Capital
vc0 recorded companies
Life-science venture capital with a documented investment in mitochondrial therapeutics for neurodegeneration through NRG Therapeutics.
M Ventures
corporate0 recorded companies
Corporate venture capital of Merck KGaA, Darmstadt, Germany, with a documented investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline.
Novartis Venture Fund
corporate0 recorded companies
Corporate life-science venture investing with a disclosed investment in NRG Therapeutics' mitochondrial programs for Parkinson's disease and amyotrophic lateral sclerosis.
Criteria Bio Ventures
vc0 recorded companies
Evergreen life-science venture capital with a disclosed investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline.
Omega Funds
vc0 recorded companies
Life-science venture capital with a disclosed investment in mitochondrial therapeutics through NRG Therapeutics.
3E Bioventures Capital
vc0 recorded companies
Life-science venture capital with a disclosed investment in Lysoway Therapeutics and its lysosomal clearance programs for neurodegenerative disease.
Future Ventures
vc0 recorded companies
Early-stage venture investing with disclosed backing of Cambrian Bio and its therapeutics targeting biological drivers of aging.
British Patient Capital
government-backed0 recorded companies
UK government-owned patient-capital investment with direct life-science exposure to NRG Therapeutics' mitochondrial programs for neurodegenerative disease.
The Column Group
vc0 recorded companies
Life-science venture capital and company creation with a disclosed investment in Nura Bio's SARM1 and neuroimmune-regulation programs.
Samsara BioCapital
vc0 recorded companies
Biotechnology venture capital with a disclosed investment in Nura Bio's neuroprotective SARM1-inhibitor pipeline.
Sanofi Ventures
corporate0 recorded companies
Corporate venture capital with disclosed investments in Nura Bio's SARM1 neuroprotection programs and Rezera's NLRP3-inhibitor portfolio.
Cambridge Innovation Capital
vc0 recorded companies
Life-science and deep-tech venture capital with a disclosed formation and financing role in TRIMTECH Therapeutics' protein-aggregate degradation platform.
Pfizer Ventures
corporate0 recorded companies
Pfizer's corporate venture-investment group, with a disclosed equity investment in TRIMTECH Therapeutics' protein-aggregate degradation pipeline.
BGF
vc0 recorded companies
UK growth and early-stage investor with a disclosed equity investment in TRIMTECH Therapeutics' neurodegenerative protein-clearance programs.
Bain Capital Ventures
vc0 recorded companies
Multi-stage venture investing with a disclosed investment in Loyal and its canine longevity-drug programs.
Valor Equity Partners
vc0 recorded companies
Private investment firm with a documented investment in Loyal's canine healthy-aging and lifespan-extension platform.
Anthos Capital
vc0 recorded companies
Venture investor in consumer and technology companies with a disclosed investment in Cambrian Bio's healthspan-focused therapeutics platform.
Longitude Capital
vc0 recorded companies
Healthcare venture-growth investing with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease.
RTW Investments
vc0 recorded companies
Life-sciences investment and company creation with a disclosed investment in BioAge's aging-biology therapeutics.
Amgen Ventures
corporate0 recorded companies
Amgen's corporate venture-capital function, with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease.
Sunstone Life Science Ventures
vc0 recorded companies
European life-science venture capital with disclosed investments in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.
Sound Bioventures
vc0 recorded companies
Biotherapeutics venture capital with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.
Industrifonden
vc0 recorded companies
Swedish venture investor with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.
Innovestor Life Science Fund
vc0 recorded companies
Nordic life-science venture fund with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs.
p53 Invest
family_office0 recorded companies
Norwegian healthcare investment company with a disclosed investment in Teitur Trophics' neurodegeneration programs.
BioInnovation Institute
nonprofit0 recorded companies
Independent nonprofit life-science foundation providing company-creation programs, grants, and convertible funding to early-stage startups.
Apple Tree Partners
vc0 recorded companies
Life-science venture capital and company creation with a disclosed investment in Nine Square Therapeutics' neurodegeneration programs.
Pivotal bioVenture Partners
vc0 recorded companies
Life-sciences venture capital focused on therapeutics, with documented participation in BioAge Labs' aging-biology therapeutics financing.
Cellectis
corporate0 recorded companies
Gene-editing biotechnology company with a disclosed equity investment in Primera Therapeutics' mitochondrial-DNA editing platform.
First Round Capital
vc0 recorded companies
Early-stage venture capital with a disclosed seed investment in Loyal's canine longevity-drug programs.
Collaborative Fund
vc0 recorded companies
Venture capital with a disclosed investment in Loyal's canine healthspan and lifespan-extension programs.
Quiet Capital
vc0 recorded companies
Early-stage venture capital with a disclosed investment in NewLimit's epigenetic-reprogramming medicines for age-related disease.
OrbiMed
vc0 recorded companies
Healthcare investment across company stages with a disclosed investment in BioAge Labs' metabolic-aging therapeutics.
SV Health Investors
vc0 recorded companies
Healthcare venture and growth investing with a disclosed investment in BioAge Labs' metabolic-aging therapeutics.
Sands Capital
vc0 recorded companies
Growth investment with a life-sciences strategy and a disclosed investment in BioAge Labs' metabolic-aging therapeutics.
4P Capital
vc0 recorded companies
Venture-capital and private-equity investing with a disclosed investment in Retro Biosciences' autophagy, cellular-reprogramming and stem-cell programs for age-related disease.
Cormorant Asset Management
0 recorded companies
Life-sciences and healthcare investment across public and private biotechnology, with documented participation in BioAge Labs' aging-biology therapeutics financing.
Osage University Partners
vc0 recorded companies
Venture investment in science-driven university startups, with documented participation in BioAge Labs' aging-biology therapeutics financing.
Lilly Ventures
corporate0 recorded companies
Lilly's global biotechnology investment arm, with documented participation in BioAge Labs' aging-biology therapeutics financing.
Andreessen Horowitz
vc0 recorded companies
Multi-stage venture capital including a Bio + Health practice, with documented participation in BioAge Labs' aging-biology therapeutics financing.
BoxGroup
vc0 recorded companies
Early-stage venture capital with a disclosed investment in Loyal's canine longevity-drug programs.
Baillie Gifford
0 recorded companies
Long-term investment management with documented participation in Loyal's canine longevity-drug financing.
| Select up to four records | |||||
|---|---|---|---|---|---|
| Karl Pfleger | angel | 24 | — | — | |
| Healthspan Capital | vc | 16 | — | — | |
| Formic Ventures / Michael Antonov | vc | 13 | — | — | |
| Kizoo Tech Ventures | vc | 12 | — | — | |
| LongevityTech Fund | vc | 12 | — | — | |
| VitaDAO | angel | 12 | — | — | |
| LongGame | angel | 9 | — | — | |
| Bioverge | angel | 8 | — | — | |
| Methuselah Fund / Foundation | nonprofit | 8 | — | — | |
| Longevity Fund / age1 | — | 7 | — | — | |
| quadraScope / Fiona Miller | vc | 7 | — | — | |
| 100+ Capital / Sonia Arrison | vc | 6 | — | — | |
| FightAging! / Reason | vc | 6 | — | — | |
| Lifespan Vision Ventures | vc | 6 | — | — | |
| Longevity Fund / age1 (as of Sep 2023) | vc | 6 | — | — | |
| Jim Mellon | angel | 6 | — | — | |
| R42 Group / Ronjon Nag | vc | 6 | — | — | |
| Starbloom Capital | vc | 6 | — | — | |
| Bold Capital | vc | 5 | — | — | |
| LongeVC | angel | 5 | — | — | |
| Shanda Venture Capital | vc | 5 | — | — | |
| Longevity Vision Fund | vc | 4 | — | — | |
| Metaplanet | angel | 4 | — | — | |
| Juvenescence | angel | 4 | — | — | |
| Thynk Capital / Jim Plante | vc | 4 | — | — | |
| Emerging Longevity Ventures | vc | 3 | — | — | |
| Prime Movers Lab | angel | 3 | — | — | |
| Ahren Capital | vc | 2 | — | — | |
| Apollo Health Ventures | vc | 2 | — | — | |
| Hevolution | nonprofit | 2 | — | — | |
| Presight Capital | vc | 2 | — | — | |
| Remiges Ventures | vc | 1 | — | — | |
| Dementia Discovery Fund | vc | 0 | — | — | |
| Longevity Venture Fund I | vc | 0 | Scottsdale, Arizona, USA | Early-stage regenerative medicine, cell therapies, organ transplantation, epigenetic reprogramming, AI drug discovery, peptides, and iPSC manufacturing | |
| Khosla Ventures | vc | 0 | — | Multi-sector venture capital with aging-biology investments in senescent-cell therapeutics, canine lifespan extension, epigenetic medicine, stem-cell manufacturing, and engineered organs | |
| Healthspan Ventures | vc | 0 | — | Pre-seed and seed investment in longevity biology, AI therapeutics, diagnostics, regenerative medicine, scientific tools, and human performance | |
| Immortal Dragons | — | 0 | — | Radical life extension technologies including gene therapy, tissue engineering, organ replacement, regenerative medicine, neuroprotection, and healthspan | |
| Maximon | — | 0 | Zug, Switzerland | Longevity company building and early investment across science-based supplements, personalized diagnostics and treatment, preventive health, and healthy-aging services | |
| Korify Capital | vc | 0 | — | Longevity, mental health and regenerative medicine; Series A to C investing. | |
| ARCH Venture Partners | vc | 0 | — | Science-based venture investing with portfolio exposure to cellular rejuvenation, mitochondria and neurodegeneration. | |
| Leaps by Bayer | corporate | 0 | — | Strategic life-science investment including regenerative cell therapies, neurodegeneration and chronic inflammation. | |
| Sofinnova Investments | vc | 0 | — | Healthcare and life-science investing with a documented investment in BioAge Labs and its therapeutics targeting the biology of aging. | |
| RA Capital Management | vc | 0 | — | Multi-stage healthcare investing with a documented investment in BioAge Labs. | |
| Jetstream Venture Fund | vc | 0 | — | Venture investing with exposure to gene therapy for chronic and age-related diseases and animal health. | |
| Kendall Capital Partners | vc | 0 | — | Early-stage biotechnology and life sciences, including gene therapy for age-related disease. | |
| VCapital | vc | 0 | — | Venture investing with exposure to gene therapy for age-related disease and companion-animal health. | |
| KdT Ventures | vc | 0 | — | Venture investing with documented exposure to age-related disease gene therapy. | |
| Digitalis Ventures | vc | 0 | — | Venture investing with exposure to human and companion-animal health through age-related disease gene therapy. | |
| Dolby Family Ventures | vc | 0 | — | Early-stage precision neuroscience and life-science platforms, including mitochondrial quality control. | |
| Versant Ventures | vc | 0 | — | Biotechnology venture creation and investing, including regenerative cell therapies. | |
| Founders Fund | vc | 0 | — | Broad technology venture capital with a documented investment in epigenetic-reprogramming therapeutics through NewLimit. | |
| Kleiner Perkins | vc | 0 | — | Broad venture capital with a documented investment in aging-biology therapeutics through NewLimit. | |
| Dimension | vc | 0 | — | Science-and-compute investment firm with a documented investment in NewLimit's cellular-reprogramming platform. | |
| Goldcrest Capital | vc | 0 | — | Broad venture capital with a documented investment in Junevity's cell-reset and siRNA therapeutics platform. | |
| Connecticut Innovations | vc | 0 | — | State-backed venture investment with documented exposure to gene therapies for age-associated and chronic disease through Rejuvenate Bio. | |
| Brandon Capital | vc | 0 | — | Life-science venture capital with a documented investment in mitochondrial therapeutics for neurodegeneration through NRG Therapeutics. | |
| M Ventures | corporate | 0 | — | Corporate venture capital of Merck KGaA, Darmstadt, Germany, with a documented investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline. | |
| Novartis Venture Fund | corporate | 0 | — | Corporate life-science venture investing with a disclosed investment in NRG Therapeutics' mitochondrial programs for Parkinson's disease and amyotrophic lateral sclerosis. | |
| Criteria Bio Ventures | vc | 0 | — | Evergreen life-science venture capital with a disclosed investment in NRG Therapeutics' mitochondrial neurodegeneration pipeline. | |
| Omega Funds | vc | 0 | — | Life-science venture capital with a disclosed investment in mitochondrial therapeutics through NRG Therapeutics. | |
| 3E Bioventures Capital | vc | 0 | — | Life-science venture capital with a disclosed investment in Lysoway Therapeutics and its lysosomal clearance programs for neurodegenerative disease. | |
| Future Ventures | vc | 0 | — | Early-stage venture investing with disclosed backing of Cambrian Bio and its therapeutics targeting biological drivers of aging. | |
| British Patient Capital | government-backed | 0 | — | UK government-owned patient-capital investment with direct life-science exposure to NRG Therapeutics' mitochondrial programs for neurodegenerative disease. | |
| The Column Group | vc | 0 | — | Life-science venture capital and company creation with a disclosed investment in Nura Bio's SARM1 and neuroimmune-regulation programs. | |
| Samsara BioCapital | vc | 0 | — | Biotechnology venture capital with a disclosed investment in Nura Bio's neuroprotective SARM1-inhibitor pipeline. | |
| Sanofi Ventures | corporate | 0 | — | Corporate venture capital with disclosed investments in Nura Bio's SARM1 neuroprotection programs and Rezera's NLRP3-inhibitor portfolio. | |
| Cambridge Innovation Capital | vc | 0 | — | Life-science and deep-tech venture capital with a disclosed formation and financing role in TRIMTECH Therapeutics' protein-aggregate degradation platform. | |
| Pfizer Ventures | corporate | 0 | — | Pfizer's corporate venture-investment group, with a disclosed equity investment in TRIMTECH Therapeutics' protein-aggregate degradation pipeline. | |
| BGF | vc | 0 | — | UK growth and early-stage investor with a disclosed equity investment in TRIMTECH Therapeutics' neurodegenerative protein-clearance programs. | |
| Bain Capital Ventures | vc | 0 | — | Multi-stage venture investing with a disclosed investment in Loyal and its canine longevity-drug programs. | |
| Valor Equity Partners | vc | 0 | — | Private investment firm with a documented investment in Loyal's canine healthy-aging and lifespan-extension platform. | |
| Anthos Capital | vc | 0 | — | Venture investor in consumer and technology companies with a disclosed investment in Cambrian Bio's healthspan-focused therapeutics platform. | |
| Longitude Capital | vc | 0 | — | Healthcare venture-growth investing with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease. | |
| RTW Investments | vc | 0 | — | Life-sciences investment and company creation with a disclosed investment in BioAge's aging-biology therapeutics. | |
| Amgen Ventures | corporate | 0 | — | Amgen's corporate venture-capital function, with a disclosed investment in BioAge's aging-biology therapeutics for metabolic disease. | |
| Sunstone Life Science Ventures | vc | 0 | — | European life-science venture capital with disclosed investments in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs. | |
| Sound Bioventures | vc | 0 | — | Biotherapeutics venture capital with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs. | |
| Industrifonden | vc | 0 | — | Swedish venture investor with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs. | |
| Innovestor Life Science Fund | vc | 0 | — | Nordic life-science venture fund with a disclosed investment in Teitur Trophics' mitochondrial and lysosomal neurodegeneration programs. | |
| p53 Invest | family_office | 0 | — | Norwegian healthcare investment company with a disclosed investment in Teitur Trophics' neurodegeneration programs. | |
| BioInnovation Institute | nonprofit | 0 | — | Independent nonprofit life-science foundation providing company-creation programs, grants, and convertible funding to early-stage startups. | |
| Apple Tree Partners | vc | 0 | — | Life-science venture capital and company creation with a disclosed investment in Nine Square Therapeutics' neurodegeneration programs. | |
| Pivotal bioVenture Partners | vc | 0 | — | Life-sciences venture capital focused on therapeutics, with documented participation in BioAge Labs' aging-biology therapeutics financing. | |
| Cellectis | corporate | 0 | — | Gene-editing biotechnology company with a disclosed equity investment in Primera Therapeutics' mitochondrial-DNA editing platform. | |
| First Round Capital | vc | 0 | — | Early-stage venture capital with a disclosed seed investment in Loyal's canine longevity-drug programs. | |
| Collaborative Fund | vc | 0 | — | Venture capital with a disclosed investment in Loyal's canine healthspan and lifespan-extension programs. | |
| Quiet Capital | vc | 0 | — | Early-stage venture capital with a disclosed investment in NewLimit's epigenetic-reprogramming medicines for age-related disease. | |
| OrbiMed | vc | 0 | — | Healthcare investment across company stages with a disclosed investment in BioAge Labs' metabolic-aging therapeutics. | |
| SV Health Investors | vc | 0 | — | Healthcare venture and growth investing with a disclosed investment in BioAge Labs' metabolic-aging therapeutics. | |
| Sands Capital | vc | 0 | — | Growth investment with a life-sciences strategy and a disclosed investment in BioAge Labs' metabolic-aging therapeutics. | |
| 4P Capital | vc | 0 | — | Venture-capital and private-equity investing with a disclosed investment in Retro Biosciences' autophagy, cellular-reprogramming and stem-cell programs for age-related disease. | |
| Cormorant Asset Management | — | 0 | — | Life-sciences and healthcare investment across public and private biotechnology, with documented participation in BioAge Labs' aging-biology therapeutics financing. | |
| Osage University Partners | vc | 0 | — | Venture investment in science-driven university startups, with documented participation in BioAge Labs' aging-biology therapeutics financing. | |
| Lilly Ventures | corporate | 0 | — | Lilly's global biotechnology investment arm, with documented participation in BioAge Labs' aging-biology therapeutics financing. | |
| Andreessen Horowitz | vc | 0 | — | Multi-stage venture capital including a Bio + Health practice, with documented participation in BioAge Labs' aging-biology therapeutics financing. | |
| BoxGroup | vc | 0 | — | Early-stage venture capital with a disclosed investment in Loyal's canine longevity-drug programs. | |
| Baillie Gifford | — | 0 | — | Long-term investment management with documented participation in Loyal's canine longevity-drug financing. |